Navigation Links
Copper Eliminates Resistant Hospital Germs in a Worldwide Field Test
Date:8/22/2008

ubt that copper surfaces can efficiently kill bacteria and other germs," Prof. Dr. Dietrich H. Nies, Director of the Institute for Biology at the Martin Luther University Halle-Wittenberg, Germany, also confirms.

With its field test (two times eight weeks with weekly periodic sampling), the Asklepios Clinic Wandsbeck is involved in a worldwide study program. Comparable studies under clinical conditions are planned or are being performed at the same time in Great Britain, South Africa, the US and Japan. In Wandsbek, samples from door handles, door plates and light switches were collected during the last weeks: both from common surfaces, e.g. made of stainless steel, and from surfaces with cooper alloys. Experience has shown that door handles and light switches are the most frequent surfaces of transmission.

50,000 casualties in Europe alone every year

According to serious estimates, more than half a million of such nosocomial infections - i.e. caught in the clinic - occur every year, in German hospitals alone. According to the European Centre for Disease Prevention and Control (ECDC), there are three million cases all over Europe, of which 50,000 are fatal. Antibiotic-resistant germs like MRSA (MRSA stands for Methicillin-resistant Staphylococcus aureus) present a particularly high danger in this context.

In addition to the partly life-threatening danger for the patients, there is also an enormous economic damage which might amount to billions in Germany alone. For the US, there is an estimate by the Center for Disease Control (CDC), according to which nosocomial infections incur costs of more than 4.5 billion US dollars. In Great Britain, the National Health Service (NHS) estimates the additional costs at one billion pounds sterling every year. According to estimates, patients who contract MRSA in the clinic stay in sickbed up to four days longer on average and incur additional costs to the amount of 4,000 Euro, in individual cases even u
'/>"/>

SOURCE Asklepios Kliniken
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
2. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
3. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
4. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
5. June 2008 Mayo Clinic Womens HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing
6. Kosans Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial
7. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
8. Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy
9. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
10. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
11. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...ATO,Calif.,Nov.23/PRNewswire-FirstCall/--RaptorPha...PTP ),todayannouncedresultsfromaPhase2bclinicaltri...ate("DRCysteamine")inpatientswithnephropathiccysti...ityofCalifornia,SanDiego("UCSD")GeneralClinicalRes...ineticsandpharmacodynamicsofasingledoseofDRCysteam...
(Date:11/23/2009)...VERN,Pa.andFRAZER,Pa.,Nov.23/PRNewswire-FirstCall/...ceuticalcompany,andCephalon,Inc.(Nasdaq: CEPH )tod...rCINQUIL(TM)(reslizumab)asatreatmentforpediatriceo...aluateimprovementintheco-primaryendpointsofchanges...alysesofthedataindicatedthatpatientstreatedwithCIN...
(Date:11/23/2009)...INE,Calif.,Nov.23/PRNewswire/--AdvancedSterilizati...olutionprovider,announcedtodaytheacquisitionbyitsF...elyhelddeveloperofinnovativedisinfectionprocessesa...ns.Termsoftheacquisitionwerenotdisclosed. ,, Gl...aminationtechnologythatprovidesdisinfectionofpatie...
Breaking Medicine Technology:Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 5Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 2Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 3Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis 4ASP Announces Acquisition of Gloster Europe to Help Reduce Infections in Healthcare Facilities 2AMDL Inc Announces Second Quarter 2009 Financial Results 54924 1AMDL Inc Announces Second Quarter 2009 Financial Results 54924 2AMDL Inc Announces Second Quarter 2009 Financial Results 54924 3AMDL Inc Announces Second Quarter 2009 Financial Results 54924 4AMDL Inc Announces Second Quarter 2009 Financial Results 54924 5AMDL Inc Announces Second Quarter 2009 Financial Results 54924 6AMDL Inc Announces Second Quarter 2009 Financial Results 54924 7Stenting a Good Option for Left Main Heart Artery 54922 1Stenting a Good Option for Left Main Heart Artery 54922 2Stenting a Good Option for Left Main Heart Artery 54922 3Chindex International Inc Announces New CDC Contract 54917 1Chindex International Inc Announces New CDC Contract 54917 2Chindex International Inc Announces New CDC Contract 54917 3
...an Biosciences,Incorporated (Nasdaq: KOSN ) today...tanespimycin, the company,s lead Hsp90 inhibitor, ...(R) in patients with HER2-positive,metastatic brea...can,Society of Clinical Oncology (ASCO), being hel...une 3, 2008., Abstract 1027, titled, "Phase 2 tri...
... Review Data Tuesday, May 13 at 1:00 p.m. EDT ...A, Spain and MENLO PARK, Calif., May 13 /PRNewswir... announced positive six-month follow-up,data from ...safety and,efficacy of the Custom NX(R) drug eluti...s with coronary artery disease., The CUSTOM III c...
Other Medicine Technology:Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 2Kosan Announces Data Presentations at ASCO 2008 Annual Meeting 3XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 2XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 3XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting 4
(Date:11/23/2009)...age are more than twice as likely to develop demen...the Sahlgrenska Academy. , The study has just be.... , "Anyone carrying a lot of fat around the mid... a heart attack or stroke," says Deborah Gustafson...they nevertheless manage to live beyond 70, they r...
(Date:11/23/2009)... of Agriculture (USDA) has awarded a two-year, $90... Minnesota to complete sequencing the genome of th...nding will be used by the Turkey Genome Sequencing...g next-generation sequencing platforms, assemble t...ns in the final genome sequence by use of a sophis...
(Date:11/23/2009)...lationHealthPrograms ,, LOVELAND,Ohio,Nov.23/P...stitute(PHII),anon-profit501(c)(3)organization,isp...ovedtheHealthcareTransparencyAccreditationProgram,...M),alife,health,andwellnesscompanybasedinFarmingto...tationsealforfiveofitsprograms. ,, ThomasW.Wils...
(Date:11/23/2009)...il to the diet could reduce the risk of osteoporos...s, according to a report to be published in the I... Public Health . , Mer Harvi and colleagues at t... studied the effect of diabetes on bone health and...y the onset of osteoporosis. The researchers studi...
(Date:11/23/2009)...re blacks die than whites, study finds , ... and co-existing health problems don,t explain why...ates than whites, U.S. researchers say. , In an...l rates than whites for nearly all cancers, includ...ariety factors, such as differences in health care...
Breaking Medicine News(10 mins):Health News:Turkey Genome Sequencing Consortium awarded $0.9 million from USDA 2Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 2Health News:Population Health Impact Institute Launches Healthcare Transparency Accreditation Program(TM) 3Health News:Flaxseed oil and osteoporosis 2Health News:Weight May Not Drive Racial Disparities in Colon Cancer 2
... Embraces Cutting-Edge Patient Safety ...Hoana Medical, Inc. announced a,partnership with K...olulu,Hawai,i, to deliver cutting-edge vigilance t...e LifeBed(TM) Patient,Vigilance System (LifeBed) t...
...ef Robert Weiner Says Calls for,Privatization and ...reet,Giveaway Turning Guarantee to Gamble, WASHIN...ry August 14, ex-U.S. House Committee on Aging Chi...iveaway which would turn Social Security from a gu...
...Contest Developed Innovative Technology To ...ITTSBURGH, Aug. 13 A team of students from the Te...ity will ring The NASDAQ Stock,Market Opening Bell...mpetition, the annual business school contest know...
...nc. ("Assurant"),(NYSE: AIZ ), a premier provider...ucts and services, announced today that Jane Meyer...esources, and Allen Walker,has been appointed seni...nd Mr. Walker will continue to report to Assurant,...
...fault for treatment gaps affecting 1 in every 100 ...y News) -- About one in 100 American adults has ac...h epilepsy aren,t receiving adequate treatment, ac...ults in 19 states. , "Despite having recent seizu...
... might think they are saving significantly more by...ey most likely will be disappointed or could be t...to MSU research. , Professor Jerry Punch of the ...ished their study on over-the-counter hearing aids...
Other Medicine News:Health News:Hoana Medical, Inc. Partners With Kahala Nui to Improve Patient Safety 2Health News:Hoana Medical, Inc. Partners With Kahala Nui to Improve Patient Safety 3Health News:Hoana Medical, Inc. Partners With Kahala Nui to Improve Patient Safety 4Health News:Social Security's 73rd Anniversary 2Health News:Tepper School Start-Up to Ring Nasdaq Stock Market Opening Bell 2Health News:Tepper School Start-Up to Ring Nasdaq Stock Market Opening Bell 3Health News:Assurant Announces Two Executive Appointments 2Health News:Epilepsy Receiving Inadequate Attention 2Health News:Study finds not all hearing aids are created equal 2
...6 mm tip is angled 90 degrees with 1 mm flattened ...ure extension tube (0.03 inch ID x 8 inch long), f...r dissecting pre-retinal and other vitreo-retinal ..., angled tip of 30 gauge cannula facilitates place...
Vitreoretinal Micro Cannula
Moist Air Humidifying Chambers
Eye Garter Shield Cover - white
Medicine Products: